At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, it was a pleasure to meet Jose Juanatey to discuss the latest insights in making guideline-directed treatment decisions in everyday practice.
Questions
1. How can we optimise patient involvement in therapeutic decision making? (0:05)
2. What are the most important factors to consider when considering treatment intensification beyond metformin? (1:40)
3. How have the findings of recent cardiovascular outcomes trials affected treatment decisions in patients with T2D? (3:30)
4. Which patients are most likely to benefit from SGLT2 inhibitors? (4:50)
What are the major talking points at this year’s EASD meeting? (6:24)
Jose Juanatey has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
